EcoDrugPlus

Cholinergic Receptor Muscarinic 1

Ensembl ID : ENSPPRG00000015634
Gene Symbol: CHRM1
4 Cross references
101 Possible Orthologues:

Cholinergic Receptor Muscarinic 2

Ensembl ID : ENSPPRG00000019512
Gene Symbol: CHRM2
4 Cross references
259 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSPPRG00000019991
Gene Symbol: CHRM3
4 Cross references
255 Possible Orthologues:

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSPPRG00000021661
Gene Symbol: CHRM4
4 Cross references
184 Possible Orthologues:

Cholinergic Receptor Muscarinic 5

Ensembl ID : ENSPPRG00000011187
Gene Symbol: CHRM5
4 Cross references
263 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSPPRG00000022854
Gene Symbol: CHRNA3
3 Cross references
207 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 4 Subunit

Ensembl ID : ENSPPRG00000004145
Gene Symbol: CHRNA4
3 Cross references
204 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 7 Subunit

Ensembl ID : ENSPPRG00000020094
Gene Symbol: CHRNA7
4 Cross references
243 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSPPRG00000002059
Gene Symbol: CHRNB2
4 Cross references
197 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSPPRG00000023285
Gene Symbol: CHRNB4
3 Cross references
198 Possible Orthologues:

Chymase 1

Ensembl ID : ENSPPRG00000006673
Gene Symbol: CMA1
4 Cross references
293 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSPPRG00000001748
Gene Symbol: F2R
4 Cross references
327 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).